As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
20 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
20 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 209 209 |
34%
34%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | 26 26 |
83%
83%
|
|
| EBIT (Operating Income) EBIT | 24 24 |
84%
84%
|
|
| Net Profit | 52 52 |
69%
69%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
| Head office | United States |
| CEO | Dinesh Patel |
| Employees | 126 |
| Founded | 2006 |
| Website | www.protagonist-inc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


